Effects of Smoked Marijuana on Neuropathic Pain

Sponsor

Center for Medicinal Cannabis Research (Other)

Overall Status

Completed

CT.gov ID

NCT00254761

Collaborator

(none)

Enrollment

Location

Arms

Duration (Months)

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

To determine if smoking marijuana will reduce neuropathic pain without causing too much drowsiness or feeling "too dopey".

Condition or Disease	Intervention/Treatment	Phase
Neuropathic Pain	Drug: Cannabis	Phase 1/Phase 2

Detailed Description

The case for marijuana's medical use for pain is primarily from experimental studies with normal subjects, which have yielded conflicting results. Experimental subjects have been shown to have significant dose-dependant antinociception effect that is not reversed by opioid antagonism. In contrast to this positive antinociceptive effect, other experiments demonstrated hyperalgesic activity and probably enhancement of the perception of pain upon acute exposure in chronic users of marijuana.

In addition to studying spontaneous pain antinociception, it would be useful to evaluate the response to marijuana following evoked pain. Such evoked pain is produced by stimulation of the skin that is normally not noxious.

Because of the potential side effects of marijuana administration, one of the aims of the present study is to analyze inter-individual variability and the occurrence of dose-dependant analgesia of marijuana with an eye on defining tolerable dosing in clinical neuropathic pain syndromes.

Comparisons: Neuropathic and experimentally induced pain scores will be compared after the administration of escalating doses of low, high, and placebo marijuana cigarettes as provided by the National Institutes on Drug Abuse (NIDA).

Study Design

Study Type:

Interventional

Actual Enrollment :

28 participants

Allocation:

Randomized

Intervention Model:

Crossover Assignment

Masking:

Triple (Participant, Investigator, Outcomes Assessor)

Primary Purpose:

Treatment

Official Title:

A Double Blind, Active Placebo Controlled Crossover Trial of the Antinociceptive Effect of Smoked Marijuana on Subjects With Neuropathic Pain; Correlation With Changes in Mood, Cognition, and Psychomotor Performance

Study Start Date :

Nov 1, 2003

Actual Primary Completion Date :

Feb 1, 2006

Actual Study Completion Date :

Feb 1, 2006

Arms and Interventions

Arm	Intervention/Treatment
Experimental: 1 High dose cannabis (7.5% THC by weight)	Drug: Cannabis
Experimental: 2 Low dose cannabis (3.5% THC by weight)	Drug: Cannabis
Placebo Comparator: 3 Placebo cannabis	Drug: Cannabis

Arm

Intervention/Treatment

Experimental: 1

High dose cannabis (7.5% THC by weight)

Drug: Cannabis

Experimental: 2

Low dose cannabis (3.5% THC by weight)

Drug: Cannabis

Placebo Comparator: 3

Placebo cannabis

Drug: Cannabis

Outcome Measures

Primary Outcome Measures

Score on a series of pain scales (heat pain threshold, VAS intensity, VAS unpleasantness, pain relief, neuropathic pain scale). []

Secondary Outcome Measures

Number of subjects who are unable to tolerate the high dose without significant side effects. []
Changes in mood, cognitive impairment, and psychomotor performance (mood - VAS happiness, cognition - Digit Symbol Modalities Test, psychomotor performance - Grooved Pegboard Test). []

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 70 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Able to understand English
Age greater than 18 and less than 70
VAS greater than 3/10
History of previous marijuana use (i.e., avoidance of marijuana naive subjects)
Negative urine drug screening test
Nerve Injury a.k.a. Complex Regional Pain Syndrome Type II OR
Complex Regional Pain Syndrome Type I OR
Neuropathic pain due to confirmed bilateral distal peripheral neuropathy associated with Diabetes I or II, focal nerve injury, postherpetic neuralgia, spinal cord injury with incomplete myelopathy, central pain following a stroke or focal brain lesion, or clinical definite multiple sclerosis of at least 3 months duration.

Exclusion Criteria:

Presence of another painful condition of greater severity than the neuropathic pain condition which is being studied
Unstable Type 1 or 2 diabetes defined as blood glucose more than 156 mg/dl
For diabetic subjects maintained on insulin with a stable blood glucose more than 156 mg/dl, a hemoglobin A1C level of more than 0.11 (normal range, 0.048-0.067)
History of traumatic brain injury
History of schizophrenia or a past or current history of a serious psychiatric disorder that is currently not well controlled with medications
Uncontrolled medical condition - coronary artery disease, hypertension, cerebrovascular disease, asthma, TB, COPD, opportunistic infection, malignancy requiring active treatment
Active substance abuse (alcohol or injection drugs)
Current use of marijuana (within 30 days of randomization) as determined by urine screening